Businesses
Here's a look at documents from U.S. and international businesses
Featured Stories
Positive and Clinically Meaningful Results From the Phase III KALOS and LOGOS Trials for BREZTRI in Patients With Uncontrolled Asthma Published in The Lancet Respiratory Medicine
WILMINGTON, Delaware, Feb. 14 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine (https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00457-6/fulltext) showed AstraZeneca's BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6ug))
... Show Full Article
WILMINGTON, Delaware, Feb. 14 (TNSjou) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Positive and clinically meaningful results from the Phase III KALOS and LOGOS trials for BREZTRI in patients with uncontrolled asthma published in The Lancet Respiratory Medicine
Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine (https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00457-6/fulltext) showed AstraZeneca's BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6ug))demonstrated statistically significant and clinically meaningful improvements in patients with uncontrolled asthma compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines: Symbicort (budesonide/formoterol fumarate or BFF, a standard therapeutic option), PT009 (BFF in an Aerosphere formulation) and the Symbicort and PT009 treatment groups combined./1 BREZTRI is a single-inhaler, fixed-dose triple-combination of ICS/LABA and a long-acting muscarinic antagonist (LAMA).
In a pre-specified pooled analysis of the primary endpoints across the KALOS and LOGOS trials, BREZTRI improved lung function by 76mL (95% CI 57-94 mL, unadjusted p<0.001, as measured by morning pre-dose trough FEV1 over 24 weeks) and 90mL (95% CI 72-108 mL, unadjusted p<0.001, as measured by FEV1 AUC0-3 over 24 weeks) versus dual therapy (the ICS/LABA treatment groups combined)./1
In the pooled analysis of KALOS and LOGOS, BREZTRI also demonstrated clinically meaningful reductions in the annualized rate of severe asthma exacerbations versus ICS/LABA medicines in patients with or without a recent asthma exacerbation. Full results can be found in The Lancet Respiratory Medicine.
Alberto Papi, Professor and Chair of Respiratory Medicine at the University of Ferrara, and Director of the Respiratory Unit, CardioRespiratory Department, S. Anna University Hospital, Ferrara, Italy, and primary investigator, said: "Many of the 262 million people worldwide living with asthma remain uncontrolled and still struggle with symptoms like frequent breathlessness, coughing and wheezing despite the use of dual maintenance therapy. The KALOS and LOGOS trials show that the single fixed-dose triple therapy budesonide/glycopyrronium/formoterol, which combines the efficacy of an ICS, LAMA, and LABA, improved lung function, and, importantly, prevented future severe exacerbations in patients, regardless of exacerbation history."
Sharon Barr, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: "With so many patients still experiencing the debilitating effects of uncontrolled asthma, we are excited about the potential for BREZTRI to improve lung function as well as prevent exacerbations in asthma. Building on its well-established profile in COPD, we hope to bring BREZTRI to patients with uncontrolled asthma as quickly as possible."
There were no new safety or tolerability signals identified for BREZTRI in KALOS or LOGOS.
BREZTRI is an inhaled triple-combination therapy approved for the treatment of chronic obstructive pulmonary disease (COPD) in adults in more than 80 countries worldwide including the US, EU, China and Japan. Regulatory filings for BREZTRI in asthma are currently under review in all major regions.
BREZTRI AEROSPHERE(R) (budesonide, glycopyrrolate, and formoterol fumarate) Inhalation Aerosol
* BREZTRI is contraindicated in patients who have a hypersensitivity to budesonide, glycopyrrolate, formoterol fumarate, or product excipients
* BREZTRI is not indicated for treatment of asthma. Long-acting beta2-adrenergic agonist (LABA) monotherapy for asthma is associated with an increased risk of asthma-related death. These findings are considered a class effect of LABA monotherapy. When a LABA is used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone. Available data do not suggest an increased risk of death with use of LABA in patients with COPD
* BREZTRI should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition
* BREZTRI is NOT a rescue inhaler. Do NOT use to relieve acute symptoms; treat with an inhaled short-acting beta2-agonist
* BREZTRI should not be used more often than recommended; at higher doses than recommended; or in combination with LABA-containing medicines, due to risk of overdose. Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs
* Oropharyngeal candidiasis has occurred in patients treated with orally inhaled drug products containing budesonide. Advise patients to rinse their mouths with water without swallowing after inhalation
* Lower respiratory tract infections, including pneumonia, have been reported following ICS. Physicians should remain vigilant for the possible development of pneumonia in patients with COPD as the clinical features of pneumonia and exacerbations frequently overlap
* Due to possible immunosuppression, potential worsening of infections could occur. Use with caution. A more serious or fatal course of chickenpox or measles can occur in susceptible patients
* Particular care is needed for patients transferred from systemic corticosteroids to ICS because deaths due to adrenal insufficiency have occurred in patients during and after transfer. Taper patients slowly from systemic corticosteroids if transferring to BREZTRI
* Hypercorticism and adrenal suppression may occur with regular or very high dosage in susceptible individuals. If such changes occur, consider appropriate therapy
* Caution should be exercised when considering the coadministration of BREZTRI with long-term ketoconazole and other known strong CYP3A4 Inhibitors. Adverse effects related to increased systemic exposure to budesonide may occur
* If paradoxical bronchospasm occurs, discontinue BREZTRI immediately and institute alternative therapy
* Anaphylaxis and other hypersensitivity reactions (eg, angioedema, urticaria or rash) have been reported. Discontinue and consider alternative therapy
* Use caution in patients with cardiovascular disorders, especially coronary insufficiency, as formoterol fumarate can produce a clinically significant cardiovascular effect in some patients as measured by increases in pulse rate, systolic or diastolic blood pressure, and also cardiac arrhythmias, such as supraventricular tachycardia and extrasystoles
* Decreases in bone mineral density have been observed with long-term administration of ICS. Assess initially and periodically thereafter in patients at high risk for decreased bone mineral content
* Glaucoma and cataracts may occur with long-term use of ICS. Worsening of narrow-angle glaucoma may occur, so use with caution. Consider referral to an ophthalmologist in patients who develop ocular symptoms or use BREZTRI long term. Instruct patients to contact a healthcare provider immediately if symptoms occur
* Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction. Instruct patients to contact a healthcare provider immediately if symptoms occur
* Use caution in patients with convulsive disorders, thyrotoxicosis, diabetes mellitus, and ketoacidosis or unusually responsive to sympathomimetic amines
* Be alert to hypokalemia or hyperglycemia
* Most common adverse reactions in a 52-week trial (incidence 2%) were upper respiratory tract infection (5.7%), pneumonia (4.6%), back pain (3.1%), oral candidiasis (3.0%), influenza (2.9%), muscle spasms (2.8%), urinary tract infection (2.7%), cough (2.7%), sinusitis (2.6%), and diarrhea (2.1%). In a 24-week trial, adverse reactions (incidence 2%) were dysphonia (3.3%) and muscle spasms (3.3%)
* BREZTRI should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors and tricyclic antidepressants, as these may potentiate the effect of formoterol fumarate on the cardiovascular system
* BREZTRI should be administered with caution to patients being treated with:
- Strong cytochrome P450 3A4 inhibitors (may cause systemic corticosteroid effects)
- Adrenergic drugs (may potentiate effects of formoterol fumarate)
- Xanthine derivatives, steroids, or non-potassium sparing diuretics (may potentiate hypokalemia and/or ECG changes)
- Beta-blockers (may block bronchodilatory effects of beta-agonists and produce severe bronchospasm)
- Anticholinergic-containing drugs (may interact additively). Avoid use with BREZTRI
* Use BREZTRI with caution in patients with hepatic impairment, as budesonide and formoterol fumarate systemic exposure may increase. Patients with severe hepatic disease should be closely monitored
INDICATION
BREZTRI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
LIMITATIONS OF USE
Not indicated for the relief of acute bronchospasm or for the treatment of asthma.
Please see full BREZTRI Prescribing Information, including Patient Information.
You may report side effects related to AstraZeneca products.
Notes
Asthma
Asthma is a prevalent, chronic respiratory disease affecting as many as 262 million people worldwide,2 including over 25 million in the US./3 When uncontrolled, inflammation and muscle tightening in the airway (bronchoconstriction) may cause wheezing, breathlessness, chest tightness, coughing, and even death./2,4 Many patients remain uncontrolled despite the availability of standard of care medicines and continue to experience significant limitations on lung function and reduced quality of life./5,6
KALOS and LOGOS Phase III trials
KALOS and LOGOS were replicate confirmatory, randomised, double-blind, double-dummy, parallel group, multi-centre, 24-to-52-week variable length Phase III trials to assess the efficacy and safety of BREZTRI Aerosphere (320/28.8/9.6ug and 320/14.4/9.6ug) compared with two fixed-dose, dual-combination therapies of budesonide, an ICS, and formoterol fumarate, a LABA: Symbicort pressurised metered-dose inhaler (pMDI) and PT009 (in an Aerosphere formulation)./1,7,8 KALOS and LOGOS included approximately 4,300 randomised patients.
The trial design was optimised to evaluate the 320/28.8/9.6ug dose of BGF. The primary efficacy endpoints for the two individual trials were the change from baseline in forced expiratory volume in 1 second (FEV1) area under the curve 0 to 3 hours (AUC0-3) at Week 24 and trough FEV1 over 12-24 weeks and over 24 weeks./1,7,8 The primary endpoints and treatment comparisons in the KALOS and LOGOS trials differed according to regulatory submission approaches. The full results published in The Lancet Respiratory Medicine report the pooled analysis of KALOS and LOGOS results for BREZTRI compared with the ICS/LABA treatment groups combined, and includes comparisons of BREZTRI to individual comparators arms measured across both trials in the supplement.
In addition to the two registrational trials (KALOS and LOGOS), two qualifying trials, LITHOS and VATHOS, also met their primary endpoints./9,10 LITHOS and VATHOS included approximately 1,000 randomised patients.
BREZTRI/TRIXEO Aerosphere
Budesonide/glycopyrronium/formoterol fumarate (BGF), approved under the brand name BREZTRI Aerosphere in Japan, China and the US, and TRIXERO Aerosphere in the EU, is a single-inhaler, fixed-dose triple-combination of formoterol fumarate, a LABA, glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA), with budesonide, an ICS, and delivered via the Aerosphere pMDI. BREZTRI/TRIXEO Aerosphere (320/14.4/9.6ug) is approved to treat adults with COPD in more than 80 countries worldwide including the US, EU, China, Japan, and was prescribed to more than 5.5 million patients globally in 2024./11
* * *
AstraZeneca in Respiratory & Immunology
Respiratory & Immunology, part of AstraZeneca BioPharmaceuticals, is a key disease area and growth driver to the Company.
AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The Company is committed to addressing the vast unmet needs of these chronic, often debilitating, diseases with a pipeline and portfolio of inhaled medicines, biologics and new modalities aimed at previously unreachable biologic targets. Our ambition is to deliver life-changing medicines that help eliminate COPD as a leading cause of death, eliminate asthma attacks and achieve clinical remission in immune-mediated diseases.
* * *
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca-us.com and follow the Company on social media @AstraZeneca. The contents of AstraZeneca's website do not form part of this document and no one should rely on such websites or the contents thereof in reading this document.
* * *
References
1./ Papi A, et al. Budesonide-glycopyrronium-formoterol fumarate dihydrate in uncontrolled asthma (KALOS and LOGOS): twin multicentre, double-blind, double-dummy, parallel-group, randomised, phase 3 trials. Lancet Respir. Med. 2026; https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00457-6/abstract [Last accessed: February 2026]
2./ Global Asthma Network. The Global Asthma Report 2022. [Online]. Available at: http://globalasthmareport.org/resources/Global_Asthma_Report_2022.pdf. [Last accessed: February 2026].
3./ U.S. Centers for Disease Control and Prevention (CDC). Most Recent National Asthma Data. [Online]. Available at: https://www.cdc.gov/asthma/most_recent_national_asthma_data.htm. [Last accessed: February 2026].
4./ Fernandes AG, et al. Risk factors for death in patients with severe asthma. J Bras Pneumol. 2014; 40 (4): 364-372.
5./ Davis J, et al. Burden of asthma among patients adherent to ICS/LABA: A real-world study. J Asthma. 2019 Mar;56(3):332-340.
6./ Buhl R, et al. One-year follow up of asthmatic patients newly initiated on treatment with medium- or high-dose inhaled corticosteroid-long-acting beta2-agonist in UK primary care settings. Respir Med. 2020 Feb: 162:105859.
7./ Clinicaltrials.gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (KALOS) [Online]. Available at: https://clinicaltrials.gov/study/NCT04609878?limit=25&term=KALOS&rank=1. [Last accessed: February 2026].
8./ Clinicaltrials.gov. Study to Assess PT010 in Adult and Adolescent Participants with Inadequately Controlled Asthma (LOGOS) [Online]. Available at: https://clinicaltrials.gov/study/NCT04609904?limit=25&term=LOGOS&rank=4 [Last accessed: February 2026].
9./ Clinicaltrials.gov. A 12-week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants with Inadequately Controlled Asthma (LITHOS) [Online]. Available at: https://clinicaltrials.gov/study/NCT05755906?limit=25&term=LITHOS&rank=1. [Last accessed: February 2026].
10./ Clinicaltrials.gov. A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants with Inadequately Controlled Asthma (VATHOS) [Online]. Available at: https://clinicaltrials.gov/study/NCT05202262?limit=25&term=VATHOS&rank=1. [Last accessed: February 2026].
11./ AstraZeneca Data on File. 2025. REF-270910.
* * *
Original text here: https://www.astrazeneca-us.com/content/az-us/media/press-releases/2026/Positive-and-clinically-meaningful-results-from-the-Phase-III-KALOS-and-LOGOS-trials-for-BREZTRI-in-patients-with-uncontrolled-asthma-published-in-The-Lancet-Respiratory-Medicine.html
[Category: BizPharmaceuticals]
Policy Week in Review - February 13, 2026
SAN FRANCISCO, California, Feb. 14 -- Littler, a law firm, issued the following news:
* * *
Policy Week in Review - February 13, 2026
Congressional and Administrative News
At a Glance
The Policy Week in Review, prepared by Littler's Workplace Policy Institute (WPI), sets forth WPI's updates on federal, state, and local matters.
By Shannon Meade, Jim Paretti, Alex MacDonald, and Maury Baskin
What's Happening in Washington, D.C.
Department of Homeland Security Set to Shut Down Tonight
Given Congress' inability to reach a funding agreement, the Department of Homeland Security is set to shut
... Show Full Article
SAN FRANCISCO, California, Feb. 14 -- Littler, a law firm, issued the following news:
* * *
Policy Week in Review - February 13, 2026
Congressional and Administrative News
At a Glance
The Policy Week in Review, prepared by Littler's Workplace Policy Institute (WPI), sets forth WPI's updates on federal, state, and local matters.
By Shannon Meade, Jim Paretti, Alex MacDonald, and Maury Baskin
What's Happening in Washington, D.C.
Department of Homeland Security Set to Shut Down Tonight
Given Congress' inability to reach a funding agreement, the Department of Homeland Security is set to shutdown tonight when the current short-term continuing resolution expires after midnight. The Senate attempted to advance a full year funding measure yesterday, however, the vote (52-47) failed, as it was short of the 60 votes needed to pass. Negotiations have stalled due to lack of consensus regarding reforms to U.S. Immigration and Customs Enforcement (ICE) and Customs and Border Protection (CBP). Apart from those agencies, the shutdown will impact a wider variety of the Department's agencies including Transportation Security Administration (TSA), Federal Emergency Management Agency (FEMA), Federal Law Enforcement Training Centers, the Coast Guard, and others. Both the House and Senate are in recess next week.
Industry Groups Petition NLRB for Independent Contractor Rulemaking
On February 11, several industry groups, representing the interests of millions of employers nationwide, submitted a Rulemaking Petition to the National Labor Relations Board. The petition urged the Board to adopt a proposed rule for determining independent contractor status under the National Labor Relations Act. The petition argued that such a rule would restore the certainty and clarity provided by application of the common-law test as set forth in the Board's decision in SuperShuttle. It also stated that the rule would better align with judicial precedent and the current administration's views.
Democratic Leaders Introduce Paid Sick Leave Legislation
Senator Bernie Sanders (I-VT), Ranking Member of the Senate Health, Education, Labor and Pensions Committee and Rosa DeLauro (D-CT), Ranking Member of the House Appropriations Committee, introduced legislation titled, "The Healthy Families Act," which would guarantee paid sick leave to every American worker. The legislation is endorsed by the AFL-CIO, Service Employees International Union (SEIU), United Auto Workers (UAW), Communications Workers of America (CWA), Transport Workers Union (TWU), Association of Flight Attendants-CWA (AFA-CWA), International Association of Machinists (IAM), United Food and Commercial Workers (UFCW), American Federation of State, County, and Municipal Employees (AFSCME), National Education Association (NEA), American Federation of Teachers (AFT), Air Line Pilots Association (ALPA), and National Partnership for Women & Families.
OFCCP Poised to Produce Contractors' EEO-1 Data Following Losses in Litigation
Starting in 2018, the Center for Investigative Reporting (CIR) and a CIR reporter have been fighting to force OFCCP to disclose EEO-1 reports that have been filed by federal contractors. These contractors have operated with the understanding that the government must keep such reports confidential. In July 2025, the Ninth Circuit held that the EEO-1 data must be made public. Pursuant to agreements between OFCCP and CIR, OFCCP is now getting ready to produce contractors' consolidated EEO-1 reports from 2016 through 2020. Absent a further challenge, the disclosures are scheduled to be made on February 25, 2026. For Littler's analysis, read here.
Around the States
Ohio's E-Verify Law for Nonresidential Construction Contractors Takes Effect Soon
Starting March 19, 2026, Ohio's E-Verify Workforce Integrity Act will require any "nonresidential" construction company contracting in the state of Ohio to use E-Verify and impose penalties for violations. The main provision of the Act requires any "nonresidential construction contractor, subcontractor, or labor broker to verify the employment eligibility of each employee hired to perform work on a nonresidential construction project through the E-Verify program."
California High Court Limits Use of Formatting and "Fine Print" Arguments to Defeat Arbitration
The California Supreme Court (the "Court") has confirmed that an arbitration agreement's formatting--standing alone--does not render its terms substantively unconscionable, even where the text is difficult to read. The Court rejected efforts to "double count" formatting flaws as both procedural and substantive defects. The Court also reiterated that extreme procedural deficiencies may warrant closer review of an agreement's terms and remanded the case in question for further proceedings based on issues unique to the record before it.
Fourth Circuit Allows Implementation of DEI Executive Orders to Proceed
On February 6, 2026, The U.S. Court of Appeals for the Fourth Circuit issued a final published opinion vacating the district court's preliminary injunction against several elements of Executive Order 14151, Ending Radical and Wasteful Government DEI Programs and Preferencing and Executive Order 14173, Ending Illegal Discrimination and Restoring Merit-Based Opportunity, which imposed certain requirements on federal contractors and grantees of federal funds regarding DEI.
Untangling the Varying Requirements of State and Local Fair Workweek Laws
Many localities across the United States, including Los Angeles County, Los Angeles, Berkeley, San Francisco, and Emeryville, California; New York City, New York; Philadelphia, Pennsylvania; Chicago and Evanston, Illinois; Seattle, Washington; and the state of Oregon, have enacted a category of wage and hour rules commonly referred to as "fair workweek" or "predictable scheduling" legislation. These laws are designed to provide predictable schedules to employees across myriad industries, but most commonly the retail and hospitality industries, in order to allow these employees to plan their budgets and coordinate multiple jobs and caregiving responsibilities.
Title IX Preempts Public University Labor Contract Grievance Procedure, According to New Jersey Supreme Court
The New Jersey Supreme Court ruled on January 29, 2026, that Title IX--the federal law that prohibits sex discrimination in all publicly-funded educational institutions--preempted the grievance procedure in a labor contract between Rutgers University and AFSCME Local 888. Consequently, the court overturned a lower court order that had required Rutgers to arbitrate the grievance of a union employee fired based upon a Title IX complaint against him. The court also determined that the university and union could renegotiate their grievance procedure to comply with Title IX, but did not require them to do so.
* * *
Authors
Shannon Meade
Executive Director, Workplace Policy Institute
Washington, D.C.
* * *
James A. Paretti
Shareholder
Washington, D.C.
* * *
Alexander T. MacDonald
Shareholder
Washington, D.C.
* * *
Maury Baskin
Shareholder
Washington, D.C.
* * *
Original text here: https://www.littler.com/news-analysis/asap/policy-week-review-february-13-2026
[Category: BizLaw/Legal]
Morgan Stanley Declares Dividends on Its Preferred Stock
NEW YORK, Feb. 14 -- Morgan Stanley, a multinational financial services corporation, issued the following news release on Feb. 13, 2026:
* * *
Morgan Stanley Declares Dividends on Its Preferred Stock
Morgan Stanley today declared a regular dividend on the outstanding shares of each of the following preferred stock issues:
* Floating Rate Non-Cumulative Preferred Stock, Series A - $289.61 per share (equivalent to $0.289613 per Depositary Share)
* 10 Percent Non-Cumulative Non-Voting Perpetual Preferred Stock, Series C - $25.00 per share
* Fixed-to-Floating Rate Non-Cumulative Preferred Stock,
... Show Full Article
NEW YORK, Feb. 14 -- Morgan Stanley, a multinational financial services corporation, issued the following news release on Feb. 13, 2026:
* * *
Morgan Stanley Declares Dividends on Its Preferred Stock
Morgan Stanley today declared a regular dividend on the outstanding shares of each of the following preferred stock issues:
* Floating Rate Non-Cumulative Preferred Stock, Series A - $289.61 per share (equivalent to $0.289613 per Depositary Share)
* 10 Percent Non-Cumulative Non-Voting Perpetual Preferred Stock, Series C - $25.00 per share
* Fixed-to-Floating Rate Non-Cumulative Preferred Stock,Series E - $445.31 per share (equivalent to $0.445313 per Depositary Share)
* Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series F - $429.69 per share (equivalent to $0.429688 per Depositary Share)
* Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series I - $398.44 per share (equivalent to $0.398438 per Depositary Share)
* Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series K - $365.63 per share (equivalent to $0.365625 per Depositary Share)
* 4.875 Percent Non-Cumulative Preferred Stock, Series L - $304.69 per share (equivalent to $0.304688 per Depositary Share)
* Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series M - $29.38 per share
* Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series N - $1,806.05 per share (equivalent to $18.060492 per Depositary Share)
* 4.250 Percent Non-Cumulative Preferred Stock, Series O - $265.63 per share (equivalent to $0.265625 per Depositary Share)
* 6.500 Percent Non-Cumulative Preferred Stock, Series P - $406.25 per share (equivalent to $0.406250 per Depositary Share)
* 6.625 Percent Non-Cumulative Preferred Stock, Series Q - $414.06 per share (equivalent to $0.414063 per Depositary Share)
The dividends for the Preferred Stock Series M and N are payable on March 16, 2026 to stockholders of record at the close of business on February 27, 2026.
The dividends for the Preferred Stock Series A, C, E, F, I, K, L, O, P and Q are payable on April 15, 2026 to stockholders of record at the close of business on March 31, 2026.
* * *
Morgan Stanley (NYSE: MS) is a leading global financial services firm providing a wide range of investment banking, securities, wealth management and investment management services. With offices in 42 countries, the Firm's employees serve clients worldwide including corporations, governments, institutions and individuals. For more information about Morgan Stanley, please visit www.morganstanley.com.
* * *
Original text here: https://www.morganstanley.com/press-releases/morgan-stanley-declares-dividends-on-its-preferred-stock18
[Category: BizFinancial Services]
Marcus & Millichap Facilitates $40 Million Hospitality Asset Sale in Baton Rouge
ENCINO, California, Feb. 14 -- Marcus and Millichap issued the following news release:
* * *
Marcus & Millichap Facilitates $40 Million Hospitality Asset Sale in Baton Rouge
BATON ROUGE, La. - Marcus & Millichap (NYSE: MMI), a leading commercial real estate brokerage firm specializing in investment sales, financing, research and advisory services, announced today the $40.5 million sale of the Hilton Baton Rouge Capitol Center, a 291-room hotel in Baton Rouge, Louisiana.
"This was a complex, year-long transaction involving multiple stakeholders and a nationally recognized riverfront asset,"
... Show Full Article
ENCINO, California, Feb. 14 -- Marcus and Millichap issued the following news release:
* * *
Marcus & Millichap Facilitates $40 Million Hospitality Asset Sale in Baton Rouge
BATON ROUGE, La. - Marcus & Millichap (NYSE: MMI), a leading commercial real estate brokerage firm specializing in investment sales, financing, research and advisory services, announced today the $40.5 million sale of the Hilton Baton Rouge Capitol Center, a 291-room hotel in Baton Rouge, Louisiana.
"This was a complex, year-long transaction involving multiple stakeholders and a nationally recognized riverfront asset,"said Chase Dewese, senior director investments with Marcus & Millichap. "The hotel is one of downtown Baton Rouge's most prominent hospitality properties, and the new ownership is well positioned to advance a targeted repositioning and operations strategy in a Louisiana State University-anchored market."
Dewese, along with Jack Davis, and Joce Messinger of Marcus & Millichap, in association with Steve Greer, Marcus & Millichap's broker of record in Louisiana, exclusively represented the buyer, Orlando, Florida-based Northshore Development. "The Hilton Baton Rouge Capitol Center is a wonderful, historic property, and we are excited to bring the best service and experiences to our guests," said Franz Hanning, Northshore Development CEO.
The hotel overlooks the Mississippi River from the City Center in Downtown Baton Rouge. Louisiana's Old State Capitol is two blocks away and The Louisiana Art and Science Museum, Shaw Center, Raising Cane's River Center, and The Central Green are nearby.
* * *
About Marcus & Millichap, Inc. (NYSE: MMI)
Marcus & Millichap, Inc. is a leading brokerage firm specializing in commercial real estate investment sales, financing, research and advisory services with offices throughout the United States and Canada. As of December 31, 2025, the company had 1,808 investment sales and financing professionals in over 80 offices who provide investment brokerage and financing services to sellers and buyers of commercial real estate. The company also offers market research, consulting and advisory services to clients. Marcus & Millichap closed 8,818 transactions in 2025, with a sales volume of approximately $50.9 billion. For additional information, please visit www.MarcusMillichap.com.
* * *
Original text here: https://www.marcusmillichap.com/news-events/press/2026/02/marcus-millichap-facilitates-40-million-hospitality-asset-sale-in-baton-rouge
[Category: BizRealEstate]
John Deere Announces Its 2026 Startup Collaborators
MOLINE, Illinois, Feb. 14 -- Deere and Co., a manufacturer of agricultural, construction, forestry machinery and diesel engines, issued the following news release:
* * *
John Deere Announces its 2026 Startup Collaborators
New cohort to explore advanced sensing, analytics, and automation
*
Deere & Company (NYSE: DE) announced the names of five companies chosen for its 2026 Startup Collaborator Program. The John Deere Startup Collaborator Program was launched in 2019 to enhance and deepen the company's interaction with startup companies whose technology could add value for ag, construction,
... Show Full Article
MOLINE, Illinois, Feb. 14 -- Deere and Co., a manufacturer of agricultural, construction, forestry machinery and diesel engines, issued the following news release:
* * *
John Deere Announces its 2026 Startup Collaborators
New cohort to explore advanced sensing, analytics, and automation
*
Deere & Company (NYSE: DE) announced the names of five companies chosen for its 2026 Startup Collaborator Program. The John Deere Startup Collaborator Program was launched in 2019 to enhance and deepen the company's interaction with startup companies whose technology could add value for ag, construction,and roadbuilding customers.
"Through the Startup Collaborator Program, we're working with startups whose technologies address critical challenges across the various industries we serve," said Wes Robinson, Vice President, Corporate Development & Strategy. "From real time equipment and fleet insights to advanced sensing, AI driven robotics, and digital crop intelligence, these collaborations can help us move faster in delivering practical innovations that improve precision, productivity, and sustainability for our customers."
The companies participating in the 2026 Startup Collaborator include:
* AIRS ML - An edge AI company building on-device intelligence that fuses sensing and machine learning for real-time monitoring and predictive maintenance of critical industrial and mobility assets.
* IoTag - Delivers a patented telematics solution that turns raw machine operating data into insights to optimize performance across mixed fleets for agricultural and construction customers.
* resonAg - An Australian agritech company specializing in adapting proven technologies from the medical, mining and oil and gas sectors to deliver advanced soil sensing systems for precision agriculture.
* TorqueAGI - Creating the AI foundation model that powers a new generation of enterprise robots capable of real-world reasoning and autonomy.
* Aerobotics - Helps the fruit industry make smarter, more sustainable farming decisions using drone and mobile imagery combined with industry-leading computer vision and AI. Their precision insights enable growers, packers, and shippers to accurately estimate yields and optimize operations.
"The startups in our eighth Collaborator cohort bring complementary technologies that span monitoring, sensing, AI, robotics, and data driven insights," said Colton Salyards, Principal, Corporate Development, John Deere. "Through close collaboration, we're able to explore how these innovations can translate into practical benefits for customers in agriculture and construction."
* * *
About Deere & Company
It doesn't matter if you've never driven a tractor, mowed a lawn, or operated a dozer. With John Deere's role in helping produce food, fiber, fuel, and infrastructure, we work for every single person on the planet. It all started nearly 200 years ago with a steel plow. Today, John Deere drives innovation in agriculture, construction, forestry, turf, power systems, and more.
For more information on Deere & Company, visit us at www.deere.com/en/news/.
* * *
Original text here: https://www.deere.com/en/news/all-news/2026-startup-collaborator/
[Category: BizIndustrial Materials]
JPMorganChase Declares Preferred Stock Dividends
NEW YORK, Feb. 14 -- JPMorgan Chase and Co. issued the following news release:
* * *
JPMorganChase Declares Preferred Stock Dividends
JPMorgan Chase & Co. (NYSE: JPM) ("JPMorganChase" or the "Firm") has declared dividends on the following series of the Firm's outstanding preferred stock, each of which is represented by depositary shares:
Preferred Stock Series ... Distribution (per Preferred Share) ... Distribution (per Depositary Share)
Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series II ... $158.37 ... $15.837
6.500% Fixed-Rate Reset Non-Cumulative Preferred Stock, Series OO
... Show Full Article
NEW YORK, Feb. 14 -- JPMorgan Chase and Co. issued the following news release:
* * *
JPMorganChase Declares Preferred Stock Dividends
JPMorgan Chase & Co. (NYSE: JPM) ("JPMorganChase" or the "Firm") has declared dividends on the following series of the Firm's outstanding preferred stock, each of which is represented by depositary shares:
Preferred Stock Series ... Distribution (per Preferred Share) ... Distribution (per Depositary Share)
Fixed-to-Floating Rate Non-Cumulative Preferred Stock, Series II ... $158.37 ... $15.837
6.500% Fixed-Rate Reset Non-Cumulative Preferred Stock, Series OO... $162.50 ... $16.25
The dividend payment date is Wednesday, April 1, 2026, to stockholders of record at the close of business on Monday, March 2, 2026. The floating rate period for dividends on the Series II preferred stock began on April 1, 2025.
* * *
JPMorgan Chase & Co. (NYSE: JPM) is a leading financial services firm based in the United States of America ("U.S."), with operations worldwide. JPMorganChase had $4.4 trillion in assets and $362 billion in stockholders' equity as of December 31, 2025. The Firm is a leader in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing and asset management. Under the J.P. Morgan and Chase brands, the Firm serves millions of customers in the U.S., and many of the world's most prominent corporate, institutional and government clients globally. Information about JPMorgan Chase & Co. is available at www.jpmorganchase.com.
* * *
Original text here: https://www.jpmorganchase.com/ir/news/2026/jpmc-declares-preferred-stock-dividends-2-13
[Category: BizFinancial Services]
Delta Employees Celebrate Profit Sharing Worldwide
ATLANTA, Georgia, Feb. 14 -- Delta Air Lines issued the following news:
* * *
Delta employees celebrate profit sharing worldwide
Delta's annual Valentine's Day payout totals $1.3 billion, providing employees an average of four weeks pay. The program has paid more than $11 billion in profits to employees since 2015.
*
Delta will pay its employees $1.3 billion today in profit sharing for 2025, representing 8.9% of their eligible annual earnings, or more than four weeks of extra pay on average.
Since 2007, Profit Sharing Day - traditionally timed with Valentine's Day - has been the company's
... Show Full Article
ATLANTA, Georgia, Feb. 14 -- Delta Air Lines issued the following news:
* * *
Delta employees celebrate profit sharing worldwide
Delta's annual Valentine's Day payout totals $1.3 billion, providing employees an average of four weeks pay. The program has paid more than $11 billion in profits to employees since 2015.
*
Delta will pay its employees $1.3 billion today in profit sharing for 2025, representing 8.9% of their eligible annual earnings, or more than four weeks of extra pay on average.
Since 2007, Profit Sharing Day - traditionally timed with Valentine's Day - has been the company'sannual celebration of the power of Delta people and our people-first culture.
"Sharing our success is central to our values," said Delta CEO Ed Bastian. "That's why we've paid more than $11 billion in profits directly to our employees worldwide since 2015. Congratulations to every member of the Delta team on this well-earned payout and thank you for your outstanding performance taking care of our customers in 2025."
Since its earliest days, Delta's business model has been based on the idea that investing in employees is investing in the continued success of the company. Delta employees receive 10% of the first $2.5 billion the airline earns and 20% above $2.5 billion.
This year's $1.3 billion payout, which is among the top five largest in Delta's history, is more than the rest of the industry combined.
Additionally, Delta Leadership has shared that employees will receive a pay increase in 2026. More details to follow.
This year's profit-sharing distribution spans across the globe including:
Domestic:
* Georgia - $567.9 million (43,500 employees)
* New York - $171.1 million (13,500 employees)
* Minnesota - $113.7 million (8,900 employees)
* Michigan - $112 million (8,100 employees)
* California - $84 million (6,000 employees)
* Utah - $77 million (6,300 employees)
* Washington - $75.5 million (4,700 employees)
* Florida - $30.3 million (4,300 employees)
* Massachusetts - $28.7 million (3,600 employees)
* Texas - $12.2 million (1,800 employees)
International:
* EMEAI - $4.7 million
* Latin America - $1.7 million
* NAM (Canada, U.S. Virgin Islands and Bermuda) - $1.6 million
* Asia-Pacific - $4.5 million
Delta is consistently recognized for excellence as an employer, ranking No. 15 on the Fortune 100 Best Companies to Work For(R) list, which is selected by workplace culture experts at Great Place To Work every year.
Delta also placed No. 2 in Forbes list of World's Best Employers 2025 and was featured in Forbes' list of America's best employers by state, including ranking No. 1 in Georgia, Michigan and Utah.
* * *
Original text here: https://news.delta.com/delta-employees-celebrate-profit-sharing-worldwide
[Category: BizTravel]
